Fraser Institute Media Advisory: Does lowering the price for pharmaceuticals affect the availability of medicine? New study coming Friday, July 20
VANCOUVER, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- On Friday, July 20, the Fraser Institute will release a new study on Canadian health-care policy.
Implications of the Proposed Changes to Canada’s Pharmaceutical Pricing Regulations spotlights the Trudeau government’s proposed changes to the Patented Medicine Prices Review Board (PMPRB)—a federal body that regulates the prices of all patented medicines in Canada—and highlights how those changes could affect the availability of medicine for Canadian patients.
A news release with additional information will be issued via GlobeNewswire on July 20 at 5:00 a.m. (Eastern).
MEDIA CONTACTS:
Kristina Acri, Senior Fellow
Fraser Institute
To arrange media interviews or for more information, please contact:
Bryn Weese
Media Relations Specialist, Fraser Institute
(604) 688-0221 ext. 589
bryn.weese@fraserinstitute.org
Follow the Fraser Institute on Twitter | Like us on Facebook
The Fraser Institute is an independent Canadian public policy research and educational organization with offices in Vancouver, Calgary, Toronto, and Montreal and ties to a global network of think-tanks in 87 countries. Its mission is to improve the quality of life for Canadians, their families and future generations by studying, measuring and broadly communicating the effects of government policies, entrepreneurship and choice on their well-being. To protect the Institute’s independence, it does not accept grants from governments or contracts for research. Visit www.fraserinstitute.org
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
